mAb-1.5.3

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NamemAb-1.5.3
Drug Alias NamemAb 1.5.3Anti-CD20 Monoclonal Antibody (Abgenix/Amgen/AstraZeneca)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionB-lymphocyte antigen CD20 modulators
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAbgenix Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca PlcAmgen IncAbgenix Incorporated
Active IndicationsN/A
Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A